Merck drug shows strong survival benefit in early melanoma study
This article was originally published in Scrip
Executive Summary
More than 80% of patients with advanced melanoma lived after a year of treatment with a Merck & Co experimental medicine that triggers the immune system to fight cancer, early data show.